沙利度胺
医学
来那度胺
观察研究
内科学
多发性骨髓瘤
临床终点
置信区间
总体生存率
硼替佐米
人口
临床试验
肿瘤科
环境卫生
作者
S. Verelst,Hedwig M. Blommestein,Saskia de Groot,Sebastian Gonzalez‐McQuire,Lucy DeCosta,Johan B. de Raad,Carin A. Uyl–de Groot,Pieter Sonneveld
出处
期刊:HemaSphere
[Ovid Technologies (Wolters Kluwer)]
日期:2018-08-01
卷期号:2 (4)
被引量:40
标识
DOI:10.1097/hs9.0000000000000045
摘要
Registry data are important for monitoring the impact of new therapies on treatment algorithms and outcomes, and for guiding clinical decision making in multiple myeloma (MM). This observational study analyzed real-world data from patients in the Population-based HAematological Registry for Observational Studies who were treated for symptomatic MM from 2008 to 2013 in the Netherlands. The primary endpoint was overall survival (OS) from initiation of first-line treatment. Secondary endpoints included OS and progression-free survival per treatment line, treatment patterns, and treatment response. Between 2008 and 2013, 917, 583, 283, and 139 patients had initiated first, second, third, and fourth treatment lines, respectively. Thalidomide-based regimens were the most frequently used first-line treatment (66%); bortezomib- and lenalidomide-based regimens were most often used in the second line (41% and 27%, respectively). The median OS (95% confidence interval) ranged from 37.5 months (34.8-41.8 months) in the first line to 9.2 months (6.2-12.3 months) in the fourth line. Univariate analyses showed that survival benefits were most apparent in younger patients (≤65 vs >65 years). These analyses provide important real-world information on treatment patterns and outcomes in patients with MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI